Endologix Detour System Reaches Treatment Milestone

March 20, 2025—Endologix LLC announced it has reached a milestone of 1,000 patients who have been treated with percutaneous transmural arterial bypass (PTAB) using the company’s Detour system.

According to the company, the Detour system is indicated for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200 to 460 mm in length with chronic total occlusions (100 to 425 mm) or diffuse stenosis > 70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.

Sheraz Qureshi, MD, with Northwestern Medicine Central DuPage Hospital in Winfield, Illinois, successfully treated the 1,000th patient on March 14, 2025.

“Reaching the 1,000th patient milestone is a testament to the real-world impact this therapy is having,” commented Dr. Qureshi in the Endologix press release. “For patients with long superficial femoral artery (SFA) disease, this approach is offering a new pathway to better outcomes, improved mobility, and an overall better quality of life.”

This milestone includes patients in the DETOUR1 and DETOUR2 clinical studies as well as those treated after the commercial launch in July 2023. The company announced FDA approval of the device on June 8, 2023.

According to the company, PTAB with the Detour system as an approach for treating complex peripheral arterial disease (PAD) enables physicians to percutaneously bypass lesions in the SFA by using stents routed through the femoral vein to restore blood flow to the leg. The Detour system is composed of the EndoCross device and Torus stent graft to provide a minimally invasive alternative to surgical bypass.

Endologix stated that results from the clinical trials of the Detour system highlighted its durability, safety, and efficacy. The DETOUR2 study, which enrolled 202 patients across 32 sites, demonstrated strong long-term outcomes comparable to open surgical bypass while reducing the length of stay and minimizing the complications associated with open bypass surgery.

Postmarket adoption continues to show positive real-world performance, reinforcing the role of PTAB with the Detour system in the treatment paradigm for complex PAD, advised the company.